Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$72.2 million.

  • Ascendis Pharma A's Interest Expenses fell 1364.44% to -$72.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$65.9 million, marking a year-over-year decrease of 58382.14%. This contributed to the annual value of -$233.6 million for FY2025, which is 31852.46% down from last year.
  • According to the latest figures from Q4 2025, Ascendis Pharma A's Interest Expenses is -$72.2 million, which was down 1364.44% from -$78.2 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Interest Expenses registered a high of $83.8 million during Q1 2024, and its lowest value of -$78.2 million during Q3 2025.
  • In the last 5 years, Ascendis Pharma A's Interest Expenses had a median value of $10.1 million in 2022 and averaged $6.9 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Interest Expenses surged by 2210937.59% in 2023, and later crashed by 20429.14% in 2024.
  • Ascendis Pharma A's Interest Expenses (Quarter) stood at -$447292.7 in 2021, then rose by 29.75% to -$314236.2 in 2022, then soared by 22109.38% to $69.2 million in 2023, then plummeted by 191.82% to -$63.5 million in 2024, then fell by 13.64% to -$72.2 million in 2025.
  • Its last three reported values are -$72.2 million in Q4 2025, -$78.2 million for Q3 2025, and $37.4 million during Q2 2025.